Drug metabolism in human HuH7 cells assessed as carboxylesterase-mediated (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryloxy)propanoate metabolite formation at 50 uM after 48 hrs by LC/MS/MS analysis
Subacute toxicity in ICR mouse assessed as effect on tubules at 100 to 1000 mg/kg, administered once a day via oral gavage for 14 days by hematoxylin/eosin-staining based microscopic analysis
Subacute toxicity in ICR mouse assessed as effect on glomerulus at 100 to 1000 mg/kg, administered once a day via oral gavage for 14 days by hematoxylin/eosin-staining based microscopic analysis
Subacute toxicity in ICR mouse assessed as effect on renal architecture at 100 to 1000 mg/kg, administered once a day via oral gavage for 14 days by hematoxylin/eosin-staining based microscopic analysis
Subacute toxicity in ICR mouse assessed as effect on hepatic perilobular vein at 100 to 1000 mg/kg, administered once a day via oral gavage for 14 days by hematoxylin/eosin-staining based microscopic analysis
Subacute toxicity in ICR mouse assessed as effect on appearance of hepatocytes at 100 to 1000 mg/kg, administered once a day via oral gavage for 14 days by hematoxylin/eosin-staining based microscopic analysis
Subacute toxicity in ICR mouse assessed as alteration in basic levels of SGPT at 100 to 1000 mg/kg, administered once a day via oral gavage for 14 days
Subacute toxicity in ICR mouse assessed as alteration in basic levels of SGOT at 100 to 1000 mg/kg, administered once a day via oral gavage for 14 days
Drug metabolism in human HuH7 cells assessed as nucleoside diphosphate kinase-mediated ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate metabolite formation at 50 uM after 48 hrs by LC/MS/MS analysis
Drug metabolism in human HuH7 cells assessed as UMP-CMP kinase-mediated ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyl dihydrogen phosphate metabolite formation at 50 uM after 48 hrs by LC/MS/MS analysis
Drug metabolism in human HuH7 cells assessed as carboxylesterase 1-mediated (S)-2-((R)-(((2R,3R,4R,5R)-5-(4-butyramido-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphorylamino)propanoic acid metabolite formation at 50 uM after 24 hrs by LC/MS/MS analysis
Drug metabolism in human HuH7 cells assessed as carboxylesterase-mediated (S)-2-((S)-(((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryloxy)propanoic acid metabolite formation at 50 uM after 24 hrs by LC/MS/MS analysis
Drug metabolism in human HuH7 cells assessed as HINT1-mediated ((2R,3R,4R,5R)-5-(4-butyramido-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyl dihydrogen phosphate metabolite formation at 50 uM after 48 hrs by LC/MS/MS analysis
Drug metabolism in human HuH7 cells assessed as carboxylesterase-mediated (S)-2-((S)-(((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryloxy)propanoic acid metabolite formation at 50 uM after 48 hrs by LC/MS/MS analysis